1. Prevalence of clinically significant microvascular (green) and clinically significant macrovascular (yellow) disease alone and combined microvascular and macrovascular disease combined (red) in patients with GCK-MODY (GCK), control subjects, and patients with young-onset type 2 diabetes (YT2D).
Prevalence of clinically significant microvascular (green) and clinically significant macrovascular (yellow) disease alone and combined microvascular and macrovascular disease combined (red) in patients with GCK-MODY (GCK), control subjects, and patients with young-onset type 2 diabetes (YT2D). Clinically significant microvascular disease, defined as greater than background retinopathy or persistent microalbuminuria or proteinuria; clinically significant macrovascular disease, defined as intermittent claudication, amputation, angina, myocardial infarction, or stroke.
Ali J. Chakera et al. Dia Care 2015;38:
©2015 by American Diabetes Association